Citadel Advisors - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 152 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2013. The put-call ratio across all filers is 0.41 and the average weighting 0.2%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q4 2018$22,000
-69.4%
112,873
-28.3%
0.00%
Q3 2018$72,000
-63.5%
157,432
-59.6%
0.00%
Q2 2018$197,000
-93.5%
389,327
-70.0%
0.00%
-100.0%
Q1 2018$3,023,000
+16.4%
1,297,776
+41.9%
0.00%
+100.0%
Q4 2017$2,597,000
-50.0%
914,724
-49.6%
0.00%
-75.0%
Q3 2017$5,191,000
+93.3%
1,815,010
+66.8%
0.00%
+100.0%
Q2 2017$2,686,000
+222.1%
1,088,050
+370.9%
0.00%
Q1 2017$834,000
-19.0%
231,061
-20.5%
0.00%
Q4 2016$1,029,000
-75.3%
290,470
-71.8%
0.00%
-100.0%
Q3 2016$4,162,000
+550.3%
1,030,411
+607.1%
0.00%
+200.0%
Q2 2016$640,000
+45.8%
145,729
+25.4%
0.00%0.0%
Q1 2016$439,000
-73.7%
116,230
+9.0%
0.00%
-50.0%
Q4 2015$1,672,000
+88.1%
106,622
+26.5%
0.00%
+100.0%
Q3 2015$889,000
-95.4%
84,272
-89.0%
0.00%
-94.1%
Q2 2015$19,391,000
+106.0%
768,901
+127.7%
0.02%
+88.9%
Q1 2015$9,412,000
+246.7%
337,704
+127.0%
0.01%
+200.0%
Q4 2014$2,715,000
+28.0%
148,762
-9.1%
0.00%
+50.0%
Q3 2014$2,121,000
+60.9%
163,642
+102.6%
0.00%0.0%
Q2 2014$1,318,000
-3.9%
80,761
+4.1%
0.00%0.0%
Q1 2014$1,371,000
-49.1%
77,580
-30.3%
0.00%
-50.0%
Q4 2013$2,695,000
-78.0%
111,269
-67.9%
0.00%
-78.9%
Q3 2013$12,266,000
+864.3%
346,212
+324.8%
0.02%
+850.0%
Q2 2013$1,272,00081,5010.00%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q3 2013
NameSharesValueWeighting ↓
TSP Capital Management Group, LLC 813,273$3,286,0001.66%
RTW INVESTMENTS, LP 1,243,164$5,022,0001.52%
Marcus Capital, LLC 112,200$453,0000.44%
BOGLE INVESTMENT MANAGEMENT L P /DE/ 996,178$4,024,0000.29%
Benchmark Capital Advisors 67,000$271,0000.20%
SUFFOLK CAPITAL MANAGEMENT LLC 360,299$1,456,0000.20%
COLUMBIA WANGER ASSET MANAGEMENT LLC 2,907,523$11,746,0000.15%
Virtus ETF Advisers LLC 59,537$241,0000.12%
Bellevue Group AG 160,000$646,0000.12%
PDT Partners, LLC 428,300$1,730,0000.10%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders